科济生物医药（上海）有限公司 CARSGEN THERAPEUTICS CO LTD
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
CARsgen Announces CT041 CAR T-cell Product Candidate Granted RMAT Designation by the FDA 2022-01-10 21:50
CARsgen Presents Updated Research Results on BCMA CAR T-cell Product (CT053) at 2021 ASH Annual Meeting 2021-12-13 20:00
CARsgen Receives CTA Authorization from Health Canada for CLDN18.2-targeted CAR T-cell Product CT041 2021-11-22 20:00
CARsgen Announces CAR T-cell Product Candidate CT041 Granted PRIME Eligibility by the EMA 2021-11-15 22:10
Appealing Data of CARsgen Therapeutics' CAR-T (CT041) in Advanced Gastric Cancer Presented at ESMO 2021-09-20 08:24
CARsgen Therapeutics officially listing on HKEX 2021-06-19 02:57
CARsgen Therapeutics Receives Orphan Medicinal Product Designation from the European Medicines Agency for CT041 CLDN18.2 CAR T Cells for the Treatment of Gastric Cancers 2021-03-01 19:00
CARsgen Therapeutics Presents Updated Multiple Myeloma Cell Therapy Data at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition 2020-12-06 19:00
CARsgen Therapeutics to Present Multiple Myeloma Cell Therapy Data at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition in December 2020-11-20 19:00
CARsgen Therapeutics Closes a USD 186 Million Series C Equity Financing to Accelerate Global Clinical Trials of its Cell Therapy Product Candidates 2020-11-02 19:00
CARsgen Therapeutics Granted Orphan Drug Designation by the US FDA for CT041 CLDN18.2 CAR-T Cells for the Treatment of Gastric and Gastroesophageal Junction Cancers 2020-10-05 18:00
CARsgen Therapeutics Receives IND Clearance from the NMPA for CT041 CLDN18.2-CAR-T Cells 2020-08-20 18:32
CARsgen Announces the Publication of a Novel CAR-T Technology that Improves the Efficacy of CAR-T cells Against Solid Tumors without Requiring Preconditioned Lymphodepletion 2020-08-17 18:00
CARsgen Therapeutics Receives Positive EMA Opinion on Orphan Drug Designation for Fully Human Anti-BCMA CAR-T Cells (CT053) for the Treatment of Multiple Myeloma 2020-04-27 18:00
CARsgen Appoints Yong Fan as Senior Vice President of Global Regulatory Affairs 2020-01-06 18:00
CARsgen Therapeutics Receives IND Clearance from the NMPA for AB011 Humanized Claudin18.2 Monoclonal Antibody 2019-12-09 18:00
CARsgen Announces Investigational CAR-T Therapy CT053 Granted PRIME Eligibility by the European Medicines Agency 2019-09-23 18:00
CARsgen Therapeutics Receives US FDA Orphan Drug Designation For Fully Human Anti-BCMA (B Cell Maturation Antigen) Autologous Chimeric Antigen Receptor (CAR) T Cells For The Treatment Of Multiple Myeloma 2019-08-31 10:54
CARsgen Therapeutics Receives IND Clearance for BCMA-CAR-T Cells from the U.S. FDA 2019-06-19 18:00
CARsgen Therapeutics Receives IND Clearance for BCMA-CAR-T Cells from the NMPA 2019-03-01 18:00
1 2